These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807 [TBL] [Abstract][Full Text] [Related]
4. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965 [TBL] [Abstract][Full Text] [Related]
5. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143 [TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304 [TBL] [Abstract][Full Text] [Related]
7. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib. Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688 [TBL] [Abstract][Full Text] [Related]
8. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma. Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320 [TBL] [Abstract][Full Text] [Related]
9. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196 [TBL] [Abstract][Full Text] [Related]
10. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Abdel-Wahab O; Klimek VM; Gaskell AA; Viale A; Cheng D; Kim E; Rampal R; Bluth M; Harding JJ; Callahan MK; Merghoub T; Berger MF; Solit DB; Rosen N; Levine RL; Chapman PB Cancer Discov; 2014 May; 4(5):538-45. PubMed ID: 24589925 [TBL] [Abstract][Full Text] [Related]
12. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251 [TBL] [Abstract][Full Text] [Related]
13. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330 [TBL] [Abstract][Full Text] [Related]
14. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Ng YK; Lee JY; Supko KM; Khan A; Torres SM; Berwick M; Ho J; Kirkwood JM; Siegfried JM; Stabile LP Melanoma Res; 2014 Jun; 24(3):207-18. PubMed ID: 24709886 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma. Sinik L; Minson KA; Tentler JJ; Carrico J; Bagby SM; Robinson WA; Kami R; Burstyn-Cohen T; Eckhardt SG; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK Mol Cancer Ther; 2019 Feb; 18(2):278-288. PubMed ID: 30482852 [TBL] [Abstract][Full Text] [Related]
16. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A J Transl Med; 2011 May; 9():76. PubMed ID: 21609436 [TBL] [Abstract][Full Text] [Related]
17. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552 [TBL] [Abstract][Full Text] [Related]
18. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666 [No Abstract] [Full Text] [Related]